Table 1 Character of included studies (prevention)
Study [first author, publish year] | Country | Study design | Patient populations | Sample size (MSC/control) | Average age (MSC/control) | Male (%) (MSC/control) | HLA matching | MSC source | MSC dose | Number of MSC infusions | MSC infusion timing | Maximum follow-up (month) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
J Xiang, 2017 [33] | China | RCT | ALL | 32/32 | 5.5/5.2 | 56.3%/53.1% | 6/6 | Umbilical cord | 1.0 × 106 cells/kg | Once | 4 h after HSCT | 12 |
Gao L, 2016 [9] | China | RCT | AML, MDS, ALL, | 62/62 | 18–40 (62.9%)/18–40 (69.4%) | 46.8%/48.4% | 3/6–5/6 | Umbilical cord | 3 × 107 cells | No more than 4 doses | Monthly after HSCT | 70 |
Shipounova I N, 2014 [34] | Russia | RCT | Leukemia | 39/38 | 34 (17–63) | NR | 6/6 | Bone marrow | (0.9–1.65) × 106/kg | Once | 19–54 days after HSCT | 55 |
Liu, K, 2011 [25] | China | RCT | ALL, AML, CML, high-risk patients | 27/28 | 30/31.5 | 74.1%/67.9% | 3/6–5/6 | Bone marrow | (3–5) × 105 cells/kg | Once | Within 24 h after HSCT | 33.5 |
Ning H, 2008 [24] | China | RCT | AML, CML, MDS, ALL, NHL | 10/15 | 38/37 | 90.0%/86.7% | 6/6 | Bone marrow | 3.4 × 105 cells/kg | Once | 4 h before HSCT | 36 |
Kuzmina L A, 2012 [35] | Russia | RCT | AML,MDS, ALL, CML, CLL | 19/18 | 34/29 | 42.1%/38.9% | NR | Bone marrow | 1.1 × 106 cells/kg | Once | 19-54 days (mid 30) after HSCT | 32 |
Wu K H, 2013 [36] | China | RCT | ALL, AML | 8/12 | 9.8/8.5 | 62.5%/50.0% | 4/6–5/6 | Umbilical cord | 7.2 × 106 cells/kg | Once | 4 h before HSCT | 27 |